TNGX — Tango Therapeutics Inc

TNGX

SHORT CANDIDATENeutral

Composite

26.20

Technical

37.60

Fundamental

18.60

Rank

—

Price

23.17

Hurst

0.43

As of

Nov 4, 2026

Daily

Tango Therapeutics Inc

HEALTHCAREBIOTECHNOLOGY

Tango Therapeutics is a biotechnology company developing cancer treatments based on synthetic lethality and precision medicine approaches. The firm maintains a pipeline of experimental drugs targeting various cancer types, supported by partnerships with leading research institutions. The company focuses on addressing gaps in current oncology treatment options.

Market cap

$3.7B

P/E (trailing)

—

P/E (forward)

—

PEG ratio

—

Dividend yield

—

Beta

1.22

52w range

7.37 – 34.39

Return on equity

-21.30%

Profit margin

-229.90%

Revenue growth

-100.00%

Earnings growth

0.00%

Price history

1Y: 23.17 (+185.7%) · range 7.51–32.90

Cycle position

40/ 100 cycle scoreAPPROACHING ENTRY

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 32 · NOT READY · exit proximity 0

Conviction

29/ 100 · maturity 14%

VScore.0919

Buildup.3036

EMA entry setup.3832

Fundamentals.2319

Volume profile

POC

22.50

Price vs POC

+3.0%

Overhead supply

73%

Runway

+1.0%

Value area 21.45–29.57 · 73% of 120d volume overhead · heavy supply

Get an AI analyst's read on this ticker.Open the AI analyst

Contributing sources

Source	Score	Last seen
earnings-surprise	0.967	Nov 4, 2026

Pattern & cluster

Pattern

NEUTRAL

Cluster

NEUTRAL

Forward returns

Not yet labeled — the study prices these as positions mature.